Date: November 3, 2022

Location: B.Labs at Cira Centre

Complementary, Exclusive and Invitation-Only!

Advanced Therapeutics Progress spotlighted the progress being made, and development and commercial opportunities and challenges, within the fields of gene and cell therapy across diverse therapeutic areas (oncology, rare monogenic diseases, and broader chronic conditions including those in the CNS, autoimmune, and cardiometabolic diseases).

As with Lumanity’s annual Cancer Progress conference, Advanced Therapeutics Progress was distinguished by the quality of the speaking faculty, the provocative panel topics and discussions, and opportunities to network with academic and industry luminaries and investors in the cell and gene therapy fields.   

Companies who attended:

3Sixty Pharma Solutions, Adjuvant AIG / Corebridge Financial, Aleta BioTherapeutics, Amicus Therapeutics, Aro Biotherapeutics, BioAdvance, BioCentriq, BioCurie Inc., Biofund, Bristol Myers Squibb, Cabaletta Bio, Capstan Therapeutics, Carisma Therapeutics, Carnegie Pharmaceuticals, Castle Creek Biosciences, CellVax, Center for Breakthrough Medicines, Chardan, Children’s Hospital of Philadelphia, Context Therapeutics, Everest Medicines, Fox Chase Cancer Center, Gemini Advisors LLC, Guardian Bio, HealthVerity, ImmunoMet Therapeutics, Imvax, IN8Bio, Interius BioTherapeutics, Janssen R&D, Johnson and Johnson, Kate Therapeutics, Komodo Health Landmark Bio, Leukemia and Lymphoma Society, NeuExcell Therapeutics, Novartis, Nucleate, PeterBio, Pharmaron,  Philadelphia Chamber of Commerce, Population Health Partners, Princeton Capital Advisors, Real Endpoints, Rejuvenate Bio Inc., Renovacor, Synapticure, Synkrino Biotherapeutics, Taiho Oncology, Inc., Thermo Fisher Scientific, Thomas Jefferson University, Triumvira, UPENN, Windtree Therapeutics, Zonula Inc.

Conference Agenda

12:00 Lunch

12:45-1:15 Fireside Chat: Clive Meanwell, Chairman, Partner, Population Health Partners

1:20-2:10 Mitigating Commercial Risk of Complex Therapeutics

  • Moderator: Ed Saltzman, Head, Biotech Strategy, Lumanity 
  • Panelists: 
  • Gbola Amusa, MD, CFA, Partner, CSO, Chardan
  • Sangeeta Bardhan, MBA, SVP, Commercialization Strategy and Business Development, Temple University Health System, CIO, Fox Chase Cancer Center
  • Jennifer Manning, MPA, SVP, Global Strategic Partnerships, Center for Breakthrough Medicines
  • Steven Nichtberger, MD, Chairman, CEO, Co-Founder, Cabaletta Bio 

2:20-3:10 Autoimmune Disease vs. Immuno-oncology: Two Sides of the Same Coin?

  • Moderator: Joel Sandler, Principal Cancer Cell Therapy Lead, Lumanity 
  • Panelists:
  • Vijay Bhoj, MD, PhD, Assistant Professor of Pathology and Laboratory Medicine at University of Pennsylvania School of Medicine
  • Joshua Carle, VP, Business Development, Triumvira Immunologics 
  • Arun Das, CBO, Cabaletta Bio
  • Sharon Rooney-Mayer, Executive Director, Global Disease Strategy Lead, Cell and Gene Therapies, Novartis Oncology

3:10-3:30 Break  

3:30-4:20 From Monogenic to Heterogeneous: Expansion of Advanced Therapies into Broader Disease Areas 

  • Moderator: Michael Rice, SVP, Head of Advanced Therapies, Lumanity 
  • Panelists:
  • Haig Aghajanian, Adjunct Assistant Professor of Medicine, University of Pennsylvania School of Medicine, Co-founder, VP of Research, Capstan Therapeutics
  • Scott Greenberg, COO, Aro Biotherapeutics 
  • Gurpreet Ratra, PhD, CBO, Kate Therapeutics
  • Elizabeth White, PhD, CBO/SVP of Operations, Renovacor 

4:30-5:20 Value, Access and Real World Evidence 

  • Moderator: Lisa Kerber, SVP, Global Real World Evidence Strategy, Lumanity
  • Panelists:
  • Sandy Leonard, SVP, Partnerships and RWD, HealthVerity 
  • Raymond Harvey, MPH, Senior Director, Data Science, The Janssen Pharmaceutical Companies of Johnson & Johnson
  • Roger Longman, Founder, Chairman, Real Endpoints

5:30-7:30 Reception